Non-Insulin Dependent Diabetes Mellitus (NIDDM) and Angiotensin Converting Enzyme 2 (ACE2): Diabetic Patients Treated With Antihypertensive Drugs
Phase 4
- Conditions
- NIDDM
- Registration Number
- NCT00192803
- Lead Sponsor
- Rambam Health Care Campus
- Brief Summary
This feasibility study is designed to examine modulation of the relative activities of ACE and ACE2 in diabetic patients following treatment with the angiotensin type 1 receptor (AT1R) antagonist, Candesartan.
This study will provide a closer insight to the possible involvement of the renin-angiotensin system (RAS)-related enzymatic components in development or attenuation of vascular pathogenesis.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
- Signed informed consent
- Non-smokers
- Type II DM diagnosed patients
- Blood pressure < 135/90
- Serum HbA1C > 7%
- Serum creatinine < 1mg%
- Urine microalbumin < 300 mg/day
- Body mass index (BMI) < 35 kg/m2
Read More
Exclusion Criteria
- Insulin-dependent diabetic patients
- Patient with persistent microalbuminuria
- Patient with history of severe hypertension
- Congestive heart failure
- Patient receiving renin-angiotensin-aldosterone system (RAAS)-related anti-hypertensive medications.
- Patient with major hepatic disease
Read More
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method ACE and ACE2 activities in monocytes
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Internal Ward "A", Rambam Medical Center
🇮🇱Haifa, Israel